Report / Paper metadata
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Source and limits
Source: PubMed. Stored source metadata; check the linked original before acting.
Bibliographic/status field selection only; abstracts, full text, contact fields and unselected fields omitted. No clinical interpretation.
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Identifier
- PMID 42126144
- Journal
- Oncoimmunology
- Kind
- Paper metadata